UBS analyst Alex Kramm lowered the firm's price target on CME Group to $260 from $310 and keeps a Buy rating on the shares. Estimate revisions are primarily driven by lower transaction revenue due to softer futures volumes and weaker pricing, with reduced 2026 pricing expectations and ongoing concerns about competition from products such as perpetual futures reinforcing a preference for less volume-sensitive exchange operators, the analyst tells investors in a research note.
